Merck KGaA, Darmstadt, Germany: all 522 studies

Page 5 of 6. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• Atacicept Demonstrating Dose RESponSeWithdrawnNCT01440231Phase 2
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in ItalyCompletedNCT01439061
• Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ Electromechanical Device for Growth Hormone TreatmentCompletedNCT01438528
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in HungaryCompletedNCT01402999
• Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Czech RepublicCompletedNCT01400997
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in SlovakiaCompletedNCT01400984
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in SpainCompletedNCT01376921
• Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate MofetilTerminatedNCT01369628Phase 1
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in GreeceCompletedNCT01363674
• EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and NeckTerminatedNCT01360827Phase 1
• Glucophage XR® Observational StudyTerminatedNCT01336673
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in AustraliaCompletedNCT01309555
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in SwedenCompletedNCT01307059
• A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckTerminatedNCT01303237
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in AustriaCompletedNCT01296425
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in FranceCompletedNCT01291394
• A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone TreatmentCompletedNCT01267526
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UKCompletedNCT01263457
• To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South KoreaCompletedNCT01259778
• Observational Study With Prospective and/or Retrospective Follow-up, Without Modifying Patient Treatment and Follow-up Practices for the Initial Treatment of Hypothyroidism in FranceCompletedNCT01197183
• Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth HormoneCompletedNCT01196156
• A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation/Intracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian HyperstimulationCompletedNCT01196143
• Assessment of Patient Use of a New Device: RebiSmartCompletedNCT01195870
• Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy DemonstrationCompletedNCT01195857
• A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary RevascularizationWithdrawnNCT01185015Phase 4
• A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to AdulthoodCompletedNCT01157793Phase 4
• An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)CompletedNCT01152866
• An Observational Study to Evaluate Efficacy, Safety and Clinical Outcomes of Currently Used Pharmaceutical Therapies for Controlled Ovarian Stimulation in Assisted Reproductive TechniquesCompletedNCT01149070
• An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckTerminatedNCT01142869
• A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple SclerosisCompletedNCT01142583
• An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple SclerosisCompletedNCT01142557
• An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With MitoxantroneCompletedNCT01142518
• A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)CompletedNCT01142492
• An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) PatientsCompletedNCT01142453
• An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® TherapyCompletedNCT01141751
• An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal CancerTerminatedNCT01134666
• A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing TreatmentCompletedNCT01134640
• Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis SubjectsCompletedNCT01128075
• A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) SubjectsCompletedNCT01125475
• A Post Marketing Assessment of Gonal f Solution for Injection in a Prefilled Pen for Follicular Stimulation in in Vitro Fertilisation/Embryo Transfer (IVF-ET) CyclesCompletedNCT01125462
• A Prospective, Observational Study to Assess and Evaluate the Use of Glucophage XR Therapy in the Management of Patients With Type 2 DiabetesCompletedNCT01117103
• A Study to Evaluate the Ease of Use, Local Tolerance, Safety and Effectiveness of Gonal-f® (Filled-by-mass in a Prefilled Pen)CompletedNCT01115725
• An Observational Study on the Progression of Clinically Isolated Syndrome to Multiple Sclerosis Over a 2-year PeriodCompletedNCT01112657
• A Non-interventional Study to Identify the Patients With Severe Luteinizing Hormone Deficiency in the Daily PracticeCompletedNCT01112618
• An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These ParametersCompletedNCT01112345
• A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin αCompletedNCT01111084
• An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)CompletedNCT01110993
• First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid TumorsTerminatedNCT01110083Phase 1
• An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)CompletedNCT01109654
• Bisoprolol in Hypertension: Effect on Concomitant Elevated Heart RateCompletedNCT01109043
• An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.CompletedNCT01108887
• Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.CompletedNCT01101776
• Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose RegimenTerminatedNCT01100346
• GONAL-f CONSORT (Consistency in r-hFSH Starting Doses for Individualised Treatment)CompletedNCT01100333
• AS703569 and Gemcitabine Combination in Advanced MalignanciesCompletedNCT01097512Phase 1
• A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 YearsCompletedNCT01084798
• Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine PatientsCompletedNCT01082757
• A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)CompletedNCT01082354
• A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing TreatmentCompletedNCT01082315
• A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET)CompletedNCT01081756Phase 3
• A Study Using Micronised Progesterone (Crinone® 8%) in the Luteal Phase Support of Women Undergoing in Vitro Fertilisation (IVF) and Embryo Transfer (ET)CompletedNCT01081652Phase 3
• To Evaluate the Convenience, Safety and Efficacy of Follitropin Alfa Liquid Pen Compared With Follitropin Beta Liquid PenCompletedNCT01081639Phase 3
• Metabolic Endocrinology and Growth Hormone in AdultsCompletedNCT01080755
• An Observational Study to Evaluate the Efficacy of Lodoz in a Population of Hypertensive PatientsCompletedNCT01080742
• An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM PenTerminatedNCT01080729
• A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological MalignanciesTerminatedNCT01080664Phase 1
• Rebif Compliance Support Program - Assessing Needs in Multiple SclerosisCompletedNCT01080573
• A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)CompletedNCT01080066
• Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)CompletedNCT01080053
• To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis PatientsCompletedNCT01080040
• Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)CompletedNCT01080027
• Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in ArgentinaCompletedNCT01080014
• A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in ArgentinaCompletedNCT01080001
• To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple SclerosisCompletedNCT01079975
• Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®CompletedNCT01075880
• An Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to In-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)CompletedNCT01075854
• A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and NeckWithdrawnNCT01075841
• Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in KoreaCompletedNCT01075828
• An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their CaregiversCompletedNCT01075737
• Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)CompletedNCT01075711
• Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple SclerosisCompletedNCT01074346
• An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing TreatmentTerminatedNCT01074333
• An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)CompletedNCT01074281
• A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live BirthCompletedNCT01071148
• Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone DeficiencyCompletedNCT01060488Phase 3
• r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence TrialCompletedNCT01034735Phase 1
• Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)CompletedNCT01034644
• A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring SurgeryCompletedNCT01033994Phase 1
• EMD 521873 in Advanced Solid Tumors, MTD FindingCompletedNCT01032681Phase 1
• EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid TumorsCompletedNCT01012102Phase 1
• Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee ReplacementCompletedNCT00911469Phase 1
• EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)CompletedNCT00879866Phase 1
• Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injectorCompletedNCT00738205
• Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal CancerTerminatedNCT00719199Phase 1
• A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without TreatmentCompletedNCT00702065
• Long Term Follow up Study of Predictive Markers in GHD and TS ChildrenCompletedNCT00699855
• Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLCCompletedNCT00633529Phase 1
• A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation FailureCompletedNCT00504608Phase 1/2
• r-hLIF for Improving Embryo Implantation in IVFCompletedNCT00504530Phase 1/2
• Growth Hormone in the Treatment of HIV-Associated WastingCompletedNCT00489528Phase 3

← Merck KGaA, Darmstadt, Germany overview and focus areas